Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    Two Doses of Crazy

    I’d like to take the time this morning to deal with two conspiracy theorists, and I’ll take them in order of increasing foil-hat thickness. First up is Joe Collier, an emeritus professor who writes a blog for the British Medical Journal. He notes the recent study that suggested that cell phone emissions could have a… Read More
  • Alzheimer's Disease

    An Alzheimer’s Compound Runs Into Big Trouble

    Another interesting approach to Alzheimer’s therapy has just taken a severe jolt in the clinic. Elan and Transition Therapeutics were investigating ELEND005, also known as AZD-103, which was targeted at breaking down amyloid fibrils and allowing the protein to be cleared from the brain. Unfortunately, the two highest-dose patient groups exper… Read More
  • Academia (vs. Industry)

    Short Topics From All Over

    (1) Bnet Pharma on “How Not to Write a Pharma Press Release“. Privately held Epeius is sending out bulletins loaded with phrases like “more stunning results” and “Epeius Biotechnologies draws the sword of targeted gene delivery from the stone of chemistry and physics”. If they were publicly traded, this would be… Read More
  • Alzheimer's Disease

    Amyloid in Trouble

    Here’s an interesting look at the current state of the Alzheimer’s field from Bloomberg. The current big hope is Wyeth (and Elan)’s bapineuzumab, which I last wrote about here. That was after the companies reported what had to be considered less-than-hoped-for efficacy in the clinic. The current trial is the one sorted out by APOE… Read More
  • Alzheimer's Disease

    Does Glucophage Make Alzheimer’s Worse?

    Metformin, now there’s a drug story for you. It’s a startlingly small molecule, the sort of thing that chemists look and and say “That’s a real drug?” It kicked around in the literature and the labs in the 1960s, was marketed in Europe in the 1980s but was shopped around in the US for quite… Read More
  • Alzheimer's Disease

    Short Items: India, Sanjay Gupta, Satori Pharmaceuticals

    I have a few short links for everyone today. One series of posts that you might not have seen from Xconomy is a tour of the technological hot spots of India by Boston University’s Vinit Nijhawan. It’s interesting stuff for people like me who haven’t been to the country, and he isn’t shy about pointing… Read More
  • Alzheimer's Disease

    Where Are the Drugs?

    A recent correspondence on the topic of “Why aren’t there more drugs for the big CNS disorders” got me thinking about the topic. My take, having worked in the field, is that there is still so much unmet need in that area because we just don’t understand what’s going on. It’s hard to come up… Read More
  • Alzheimer's Disease

    Rember for Alzheimer’s: Methylene Blue’s Comeback

    Today we take up the extremely interesting story of Rember, hailed in this week’s press as a potential wonder drug for Alzheimer’s. There are a lot of unusual features to this one. To take the most obvious first, the Phase II data seem to have been impressive. It’s hard to show decent efficacy in an… Read More
  • Alzheimer's Disease

    Bapineuzumab: Good For Anything or Not?

    Note: I’m still working my way through the information on the much-hyped TauRx drug, Rember – a post on that is coming. Here’s more from the same Alzheimer’s meeting, though: Elan and Wyeth unveiled the data on their widely anticipated Alzheimer’s drug bapineuzumab yesterday. This is another antibody from Elan’s shop, pa… Read More
  • Alzheimer's Disease

    Patents Stopping an Alzheimer’s Wonder Drug?

    A longtime reader sent along a very interesting example that’s being used in a new book. The Gridlock Economy by Columbia economist Michael Heller is getting some good press, including this interview over at the Wall Street Journal>’s Law Blog. Heller’s thesis is: “When too many owners control a single resource, cooperation breaks down, wea… Read More